Acute Lung Injury Market Report 2025

This Acute Lung Injury market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The acute lung injury market size has grown steadily in recent years. It will grow from $2.48 billion in 2024 to $2.6 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth during the historic period can be attributed to awareness campaigns, an increase in ICU admissions, factors such as smoking and air pollution, hospital-acquired infections, and efforts to reduce mortality rates.

The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be driven by advancements in biologics and gene therapies, government funding and grants, the development of precision medicine, regenerative medicine, stem cell therapies, and global health policy reforms. Key trends in this period include the development of biologic drugs, wearable and remote monitoring devices, inhalation-based therapies, CRISPR and gene editing technologies, and the use of biosensors for real-time analysis.

The increasing prevalence of respiratory diseases is expected to drive the growth of the acute lung injury market. Respiratory diseases encompass a range of conditions that affect the lungs and other parts of the respiratory system, leading to breathing difficulties and impaired lung function. The rising incidence of these diseases can be attributed to factors such as increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Conditions such as pneumonia can lead to acute lung injury by causing severe inflammation and damaging the alveoli, which impairs gas exchange and results in respiratory distress. For example, in September 2023, the Australian Bureau of Statistics reported a rise in the death rate from influenza and pneumonia in Australia, increasing from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, reflecting a substantial 33.54% increase. As such, the growing prevalence of respiratory diseases is fueling the expansion of the acute lung injury market.

Companies in the acute lung injury market are concentrating on developing novel treatments, such as peptide therapies, to maintain their market position. Peptide treatments involve using short chains of amino acids (peptides) as therapeutic agents for medical conditions. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based healthcare company, launched Aviptadil for treating acute respiratory distress syndrome (ARDS). This treatment offers several unique benefits, including potent vasodilatory effects that are 50 times more effective than prostacyclin, a lung protection mechanism that enhances surfactant production by binding to alveolar type II cells, anti-inflammatory properties that suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha, and immunomodulatory action to regulate immune responses in the lungs. Aviptadil has also shown clinical effectiveness in improving outcomes for patients with severe viral-related ARDS.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition strengthens Ligand's portfolio by integrating innovative therapies, particularly in immunotherapy and cancer treatment. It also expands Ligand’s research and development capabilities, opening up new revenue opportunities and reinforcing its position in the biotech industry. Apeiron Biologics AG, an Austria-based biotechnology company, is actively involved in developing treatments for acute lung injury (ALI).

Major players in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., and MediciNova Inc.

North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute lung injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acute lung injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute lung injury (ALI) is a serious condition marked by widespread inflammation and damage to the lungs, resulting in impaired oxygen exchange. It can be caused by direct factors such as pneumonia or trauma, or indirect causes such as sepsis or pancreatitis. Symptoms of ALI include shortness of breath, low oxygen levels, and respiratory distress.

The primary types of acute lung injury are direct injury and indirect injury. Direct injury occurs when damage happens as a direct result of an event, action, or incident. Treatment options for ALI include mechanical ventilation, pharmacotherapy, fluid management, and others. These therapies are utilized by a range of end users, such as hospitals, clinics, and other healthcare facilities.

The acute lung injury market research report is one of a series of new reports that provides acute lung injury market statistics, including acute lung injury industry global market size, regional shares, competitors with acute lung injury market share, detailed acute lung injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute lung injury industry. This acute lung injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute lung injury market consists of revenues earned by entities by providing services such as intensive care unit (ICU) care, mechanical ventilation, oxygen therapy, extracorporeal membrane oxygenation, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lung injury market also includes sales of mechanical ventilators, oxygen therapy products, inhaled medications, sedation and analgesics, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.